Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.3M Buy
29,282
+14,666
+100% +$5.85M 0.48% 36
2026
Q2
$5.29M Sell
14,616
-15,627
-52% -$5.35M 0.22% 102
2026
Q1
$10.6M Sell
30,243
-217
-0.7% -$77.4K 0.47% 35
2025
Q4
$10M Buy
30,460
+15,688
+106% +$4.98M 0.44% 41
2025
Q3
$4.17M Buy
14,772
+90
+0.6% +$26.1K 0.3% 62
2025
Q2
$4.1M Sell
14,682
-161
-1% -$45.6K 0.32% 59
2025
Q1
$4.63M Sell
14,843
-134
-0.9% -$39.6K 0.41% 46
2024
Q4
$3.9M Buy
14,977
+560
+4% +$166K 0.32% 61
2024
Q3
$4.65M Buy
+14,417
New +$4.72M 0.41% 50

Other funds holding AMGN

BFC Planning's AMGN Position: Q3 2026 in Review

BFC Planning increased its Amgen (AMGN) stake by 100% in Q3 2026, buying an estimated $5.85M and bringing the position to 29,282 shares worth $12.3M. The position accounts for 0.48% of the portfolio, ranked #36.

BFC Planning first reported a position in AMGN in Q3 2024 and has held it in 9 quarters since. 2,911 funds tracked by Wall St. Rank hold AMGN as of Q3 2026.

  • BFC Planning held 29,282 shares of Amgen worth $12.3M as of Q3 2026.
  • BFC Planning bought 14,666 Amgen shares in Q3 2026, an estimated $5.85M.
  • Amgen made up 0.48% of BFC Planning's portfolio in Q3 2026, its #36 holding.
  • BFC Planning first reported a position in Amgen in Q3 2024 and has held it in 9 quarters since.
  • 2,911 funds tracked by Wall St. Rank held Amgen as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.